Hip international : the journal of clinical and experimental research on hip pathology and therapy
-
Randomized Controlled Trial
Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial.
Although prophylactic tranexamic acid (TXA) is a safe, low-cost option to reduce bleeding in patients undergoing total hip replacement (THR), its optimal dose and duration is unknown. We compared the safety and effectiveness of TXA given as either a single injection or continuous infusion in THR patients, hypothesising that a second TXA dose would not offer any clinical advantages over the single injection. ⋯ The 30 mg/kg TXA single shot was as safe as continuous infusion. As it is also less cumbersome, we recommend it as part of routine care in THR patients.